Fondazione Poliambulanza — Clinical Trial Site

38 Registered trials

21 Currently recruiting

Organisation

Fondazione Poliambulanza

Location

Brescia, Italy

Identifier

ORG-100045991

Address

Via Leonida Bissolati 57, 25124, Italy

Departments

Cardiology
Digestive Endoscopy
Fondazione Poliambulanza Istituto Ospedaliero
Gastroenterology and Digestive Endoscopy Unit
Gastroenterology Complex Operative Unit
medical oncology
Medical Oncology Unit
Oncologia Medica
Oncologico
Oncology
Oncology Unit
Onology Operational Unit
Orthopedics and Traumatology
U.O. Oncologia
U.O. Oncologia Medica
U.O.ONCOLOGIA MEDICA
Unità emodinamica
Unità Operativa di Gastroenterologia ed Endoscopia Digestiva
Unita Operativa Oncologia Medica
UO Gastroenterologia ed Endoscopia Digestiva
UO Gastroentrologia ed Endoscopia Digestiva
UO Oncologia
UO Oncologia Medica

Clinical trials at this site (38)

Search interface

A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III … Pending

2024-519031-42-00 pancreatic ductal adenocarcinoma 5
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Pending

2025-521587-35-00 Metastatic colorectal cancer 5
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat… Pending

2025-523735-19-00 Metastatic Microsatellite Stable Colorectal Cancer 5
Efficacy and safety of a novel dual pH-dependent delayed-release ColeseveLam for the trEatment of bile Acid diarrhoea: a Randomized, double-… Pending

2025-523868-20-00 Bile acid diarrhoea 4
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting

2023-508015-23-00 Ovarian cancer recurrent 5 2025-04-11
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w… Recruiting

2023-507853-13-00 Ulcerative Colitis 4 2025-02-25
Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial Recruiting

2024-516874-31-00 Patients with a low-grade serous epithelial carcinoma o 5 2024-12-10
The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR… Recruiting

2024-512119-34-00 MSI-H/dMMR metastatic colorectal cancer 4 2022-06-20
ROMANCE Recruiting

2025-521319-38-00 metastatic colorectal cancer 4 2026-03-11
Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS … Recruiting

2024-519798-20-00 pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LAR 4 2026-01-15
A Study to Assess the Efficacy, Safety, and what the body does to RO7837195 in Participants with Moderately to Severely Active Ulcerative Co… Recruiting

2025-520690-39-00 Moderately to Severely Active Ulcerative Colitis (UC) 4 2025-11-04
CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met… Recruiting

2024-519322-20-00 metastatic colorectal cancer 5 2025-07-21
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type… Recruiting

2024-519481-44-00 colorectal metastatic cancer 4 2025-01-08
Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h… Recruiting

2023-509717-36-00 AF patients who have undergone successful PCI 5 2024-12-16
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRES… Recruiting

2023-506632-32-00 Metastatic colorectal cancer 5 2024-10-28
A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi… Recruiting

2023-509851-15-00 Colon cancer 5 2024-10-22
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting

2023-509551-14-00 Unresectable left sided RAS/B-RAF wild-type metastatic 5 2024-06-12
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie… Recruiting

2023-506662-31-00 Gastric or gastroesophageal cancer 4 2024-02-28
Adaptative, multicenter, randomized, double-blind, parallel-group, placebo controlled, clinical trial, on the efficacy and tolerability of d… Recruiting

2024-511961-12-00 Knee osteoarthritis 10 2023-10-12
Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re… Recruiting

2022-501308-90-00 Molecularly selected and resectable primary colorectal 4 2023-05-24
A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting

2024-514180-25-00 unresectable or metastatic HER2+ colorectal cancer 5 2022-11-21
Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minima… Recruiting

2024-515681-14-00 Stage II (pT4)/III colorectal cancer with positive circ 4 2022-05-02